Revenue
2019
2019
2020
2021
2022
2023
2024
2025
ACRO BIOMEDICAL CO., LTD. (ACBM)
Price—Loading quote
Net income
2019
2019
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2019
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 · Dec 31 | 2019 · Sep 30 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $658,500 | $1.2M | $687,964 | $193,536 | $1.4M | $8.0M | $510,000 | — | — |
| Gross profit | — | — | $0 | $140,500 | $259,500 | $159,404 | $12,096 | $135,400 | $833,400 | $51,000 | — | — |
| Research & development | — | $0 | $4.8M | $10.1M | $5.3M | — | — | — | — | — | — | — |
| Operating expenses | $154,024 | $37,958 | $8.8M | $16.0M | $8.0M | $289,867 | $434,847 | $576,953 | $317,850 | $53,248 | $43,428 | $47,490 |
| Operating income | −$154,024 | −$37,958 | −$8.8M | −$15.9M | −$7.7M | −$130,463 | −$422,751 | −$441,553 | $515,550 | −$2,248 | $43,428 | — |
| Net income | −$101,146 | −$42,297 | −$8.8M | −$15.9M | −$7.7M | −$117,453 | −$371,604 | −$370,747 | $419,660 | −$2,248 | −$43,428 | −$47,490 |
| Basic EPSper diluted share | — | — | — | — | -$0.14 | $0.00 | -$0.01 | -$0.01 | $0.01 | $0.00 | $0.00 | $0.00 |
| Diluted EPSper diluted share | $0.00 | $0.00 | -$0.15 | -$0.26 | — | $0.00 | -$0.01 | -$0.01 | $0.01 | $0.00 | $0.00 | $0.00 |